Majority of the 2.5 million Malaysians detected with liver cancer are men, Malaysian Liver Foundation president, Tan Sri Dr Mohd Ismail Merican said yesterday.
He said Sabah and Sarawak topped the list for hepatitis B in the country and attributed it to, among others, the influx of foreigners in both the states.
Kelantan, he said, recorded the highest number of cases for hepatitis A.
"Hepatitis B can be transmitted from an infected mother to her child during birth, sharing of drug injection needles or for blood transfusion," he added.
Who is the culprit.....BN Umno, definitely!
ReplyDeleteThe virus is transmitted by exposure to infectious blood or body fluids such as semen and vaginal fluids, while viral DNA has been detected in the saliva, tears, and urine of chronic carriers.
DeleteAnything also blame BN UMNO, no scientific logic at all. This is how Hepatitis B is transmitted.
You hate BN so much? Maybe you can try to live in Kelantan.
DeleteMust every issue in sabah be blamed onto the government???
Deleteyour GF dumb you, ITS BN FAULT!
DeleteYou are living with your parents & have no job, ITS BN FAULT!
You cannot buy the new Iphone 4s, ITS BN FAULT!
You dont have any friends & living in misery, ITS BN FAULT!
Palui...
Isu ini bukan salah kerajaan..
DeletePeople who wished to reduce the risk of contacting Hepatitis B can get a shot of vaccine.
ReplyDeletePrevention is better than cure!
DeleteMemang tidak masuk akal menyalahkan penyebaran penyakit hepatitis b ini pada kerajaan.
ReplyDeleteBe rational, not emotional.
DeleteBagi penyokong pembangkang, apa saja masalahnya salahkan saja pada kerajaan Barisan Nasional.
DeleteKenapa salahkan kerajaan dengan penyakit tu. gila betul..
DeleteTindakan yang wajar diperlukan dan bukannya saling menunjuk jari.
ReplyDeleteKesedaran harus ada agar penyakit ini tidak merebak lagi.
ReplyDeleteKemasukan PATI yang mendadak selain membawa masalah, memang tiada manfaat lagi.
ReplyDeletePATI ni bukan saja bawa masalah sosial, tapi jg penyakit.
DeleteMemang banyak sangat keburukan PATI yang datang di Sabah ni. Entah bilalah kebanjiran PATI ni dapat diatasi.
DeletePATI ni memang kuat 'menderma'..derma jenayah, masalah kebersihan, penyakit etc..bil hospital pun tidak bayar..
DeleteStop spreading around. Immediate action must be taken.
ReplyDeleteKerajaan harus mengambil tindakan bijak agar sebaran penyakit hepatitis b tidak berterusan.
ReplyDeleteKempen kesedaran tentang bahaya penyakit TB dan langkah penjagaan awal patut dipergiatkan lagi.
DeleteNampak macam negeri2 yang miskin yang banyak kena kes hepatitis B ni.
ReplyDeletepenularan penyakit ini haruslah dikawal.
ReplyDeleteOh my... illegal immigrants is indeed the mother of all problems. So who is the daddy?
ReplyDeleteThe immigration just has to act immediately to prevent this infection from spreading as a result of lots of illegal foreigners in the state.
ReplyDeleteMinistry of health does have to contribute to prevent it from becoming an epidemic.
ReplyDeleteMinistry of healthy must increase awareness of this disease and inform they on how to prevent getting it.
DeletePrevention they say is better than cure…we all need to be careful this time around.
ReplyDeleteThe outbreak of various disease are mainly from the illegal immigrants. If this continue, sabah will no longer be a safe and clean place to stay.Eventually, there would a downturn in the tourism sector.
ReplyDeleteHelp to prevent the spread of Hepatitis B
ReplyDeleteHopefully the government will take this matter seriously.
ReplyDeleteDisebabkan kemasukan PATI yang ramai, pelbagai masalah timbul di Sabah seperti masalah sosial, masalah kesihatan, masalah jenayah dan lain-lain lagi.
ReplyDeletePATI tu yang membawa penyakit, bagus hantar balik saja. Bikin semak saja
DeleteSeveral vaccines have been developed for the prevention of hepatitis B virus infection. These rely on the use of one of the viral envelope proteins (hepatitis B surface antigen or HBsAg). The vaccine was originally prepared from plasma obtained from people who had long-standing hepatitis B virus infection.
ReplyDeleteHowever, currently, it is made using a synthetic recombinant DNA technology that does not contain blood products. One cannot be infected with hepatitis B from this vaccine.[51]
DeleteThe risk of transmission from mother to newborn can be reduced from 20–90% to 5–10% by administering to the newborn hepatitis B vaccine (HBV 1) and hepatitis B immune globulin (HBIG) within 12 hours of birth, followed by a second dose of hepatitis B vaccine (HBV 2) at 1–2 months and a third dose at and no earlier than 6 months (24 weeks).
DeleteSince 2% of infants vaccinated will not develop immunity after the first three dose series, infants born to hepatitis B-positive mothers are tested at 9 months for hepatitis B surface antigen (HBsAg) and the antibody to the hepatitis B surface antigen (anti-HBs). If post-vaccination test results indicate that the child is still susceptible, a second three dose series at (0, 1 and 6 months) is administered.
DeleteIf the child is still susceptible after the second series, a third series is not recommended.Following vaccination, hepatitis B surface antigen may be detected in serum for several days; this is known as vaccine antigenaemia.
DeleteThe vaccine is administered in either two-, three-, or four-dose schedules into infants and adults, which provides protection for 85–90% of individuals.Protection has been observed to last 12 years in individuals who show adequate initial response to the primary course of vaccinations, and that immunity is predicted to last at least 25 years.Unlike hepatitis A, hepatitis B does not generally spread through water and food.
DeleteInstead, it is transmitted through body fluids; thus, prevention is the avoidance of such transmission: unprotected sexual contact, blood transfusions, re-use of contaminated needles and syringes, and vertical transmission during child birth. Infants may be vaccinated at birth.
DeleteBesides the WHO-recommended joint immunoprophylaxis starting from the newborn, multiple injections of small doses of hepatitis B immune globulin, or oral lamivudine in HBV carrier mothers with a high degree of infectiousness (>106 copies/ml) in late pregnancy (the last three months of pregnancy), effectively and safely prevent HBV intrauterine transmission, which provide new insight into prevention of HBV at the earliest stage.
DeleteThe hepatitis B infection does not usually require treatment because most adults clear the infection spontaneously. Early antiviral treatment may be required in fewer than 1% of people, whose infection takes a very aggressive course (fulminant hepatitis) or who are immunocompromised.
ReplyDeleteOn the other hand, treatment of chronic infection may be necessary to reduce the risk of cirrhosis and liver cancer. Chronically infected individuals with persistently elevated serum alanine aminotransferase, a marker of liver damage, and HBV DNA levels are candidates for therapy. Treatment lasts from six months to a year, depending on medication and genotype.
DeleteAlthough none of the available drugs can clear the infection, they can stop the virus from replicating, thus minimizing liver damage. Currently, there are seven medications licensed for treatment of hepatitis B infection in the United States. These include antiviral drugs lamivudine (Epivir), adefovir (Hepsera), tenofovir (Viread), telbivudine (Tyzeka) and entecavir (Baraclude), and the two immune system modulators interferon alpha-2a and PEGylated interferon alpha-2a (Pegasys).
DeleteThe use of interferon, which requires injections daily or thrice weekly, has been supplanted by long-acting PEGylated interferon, which is injected only once weekly. However, some individuals are much more likely to respond than others, and this might be because of the genotype of the infecting virus or the person's heredity.
DeleteThe treatment reduces viral replication in the liver, thereby reducing the viral load (the amount of virus particles as measured in the blood). Response to treatment differs between the genotypes.
DeleteInterferon treatment may produce an e antigen seroconversion rate of 37% in genotype A but only a 6% seroconversion in type D. Genotype B has similar seroconversion rates to type A while type C seroconverts only in 15% of cases. Sustained e antigen loss after treatment is ~45% in types A and B but only 25–30% in types C and D.
Deleteterjumpa info ni, pasal hepatitis... sharing is caring :) - Risiko Radang Hati (Hepatitis)
ReplyDeletesampaikan berita ini kepada Irene Fernandez.. bagitau dia warga tempatan Sabah tidak selamat sebab terlalu ramai warga Indon yang bawa penyakit ke negeri ini..
ReplyDelete